Clinical TrialsMedicare | Clinical TrialsPrivate Insurance | Medicare Payment FDA | Cancer Research | Stem Cell Research | Privacy | Other |
||||
LETTERS TO CEOs OF NEW JERSEY HEALTH PLANS January 11, 2000 VIA TELECOPY TO CEOs OF NEW JERSEY HEALTH PLANS: The undersigned organizations, comprising the Cancer Leadership Council, advocate on behalf of people with cancer. A longstanding priority of all our organizations has been coverage of routine patient care costs for persons enrolled in high quality cancer clinical trials. Therefore, we were very pleased to see the report in the New York Times concerning your decision to adopt such coverage. Our organizations have been involved for some time in educating patients, physicians, policymakers, and the public of the benefits of clinical research and the necessity for ready access to trials. The cancer research effort must be collaborative if it is to succeed, and we look forward to working with you in education and public awareness efforts. We would appreciate your active support of our ongoing efforts to pass federal legislation to require Medicare to cover routine patient care costs for those enrolled in cancer clinical trials and your support of a clinical trials provision in patient protection legislation. Broad access to clinical trials will benefit all of us, and you could support our work by sharing with Members of Congress your decision and urging similar action in the Medicare program and in other health plans. Sincerely, Cancer Leadership Council Alliance
for Lung Cancer Advocacy, Support and Education Back to Clinical TrialsPrivate Insurance Index About CLC | What's New | Policy
Issues | Participants' Login Copyright
© 2001-2002 Cancer Leadership Council. All rights reserved. |